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& 2014 AmeBackground: Colorectal cancer (CRC) screening reduces CRC mortality; however, for many
reasons, uninsured individuals are less likely to utilize CRC screening tests.
Purpose: To compare CRC screening behaviors and outcomes with guaiac fecal occult blood
testing (gFOBT) from 1998 to 2006 and fecal immunochemical testing (FIT) from 2006 to 2010 in a
community-based program serving uninsured patients in northern Manhattan.
Methods: In 2013, we conducted a retrospective record review of individuals agedZ50 years who
received fecal-based CRC screening at the Northern Manhattan Cancer Screening Partnership
between 1998 and 2010. Included were those with household incomer250% of the federal poverty
level, no medical insurance coverage, and who were not up to date with CRC screening. We assessed
screening positivity rate, positive predictive value, differences in the use of diagnostic colonoscopy,
colonoscopic findings, and adenoma detection rates for gFOBT versus FIT.
Results: In total, 7,710 patients completed CRC screenings (4,951 gFOBT and 2,759 FIT). The
majority were female, Hispanic, foreign born, and young at age of first screening. Compared to
gFOBT, FIT detected twice as many positive tests (3.2% vs 1.5%, pr0.001) and had a higher
adenoma detection rate (18.2 vs 11.8, p¼0.002).
Conclusions: The improved positivity and adenoma detection rates with greater number of
screening tests over time favor the use of FIT over gFOBT for colorectal screening among uninsured
populations in northern Manhattan.
(Am J Prev Med ]]]];](]):]]]–]]]) & 2014 American Journal of Preventive MedicineIntroductionIt is important but challenging to screen uninsuredpeople for colorectal cancer (CRC). Nationwide, anestimated 59% of adults aged 50–75 years were up to
date with CRC screening in 2010; however, only 21% of
those without medical insurance had completed CRC
screening.1 In New York City in 2009, 66% of all adults
aged 50 years and older were screened for CRC, including
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differences is significant, as uninsured or low-income
people are more likely to be diagnosed with late-stage,
incurable cancers.3,4
Acceptable tests for CRC screening include colono-
scopy, flexible sigmoidoscopy, and stool testing for occult
blood.5 Among these modalities, stool testing for occult
blood is the least expensive, which has led to its first-line
use in population-based screening programs.6 Testing of
the stool for occult blood can be done via guaiac fecal
occult blood testing (gFOBT) or fecal immunochemical
testing (FIT), which utilizes antibodies to human globin.
Among insured populations, the performance of FIT
appears to be superior to gFOBT,7–9 but the performance
of FIT relative to gFOBT among uninsured patients is
unknown.10–15
The Northern Manhattan Cancer Screening Partner-
ship (NMCSP) is funded by the New York State Depart-
ment of Health (NYSDOH) and the CDC. The NMCSP
has provided free breast, cervical, and colorectal cancervier Inc. Am J Prev Med ]]]];](]):]]]–]]] 1
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case management services to uninsured residents of
northern Manhattan since 1998. From 1998 to 2006,
the NMCSP utilized gFOBT for CRC screening. In 2006,
the NMCSP worked with the NYSDOH Cancer Services
Program to pilot the feasibility of the use of FIT, the
results of which were utilized to inform programmatic
policy.
The findings of the pilot study suggested that patients
preferred FIT over gFOBT because of the ease of speci-
men collection (brush versus stick); fewer specimens
required (two versus three); and the lack of dietary
restriction for FIT. The amount of time from distribution
to final results was also reduced using FIT. Based on the
findings of the pilot study and other evidence supporting
the advantages of FIT, the NMCSP transitioned from
traditional gFOBT to FIT as the primary modality for
CRC screening among average-risk individuals.
Screening behaviors and outcomes with FIT versus
gFOBT were examined by conducting a retrospective
study among NMCSP participants from 1998 to 2010.
The current study documents the program’s experience
using both gFOBT and FIT to screen uninsured, minority,
low-SES individuals in northern Manhattan for colorectal
cancer over a 13-year period. Specifically, annual CRC
screening behaviors with gFOBT and FIT, screening
positivity rate, positive predictive values for each test,
and colonoscopic findings among participants with pos-
itive fecal-based screening tests are reported here.Methods
Screening Program
The NMCSP, through grants received from NYSDOH and CDC,
provides no-cost cancer screening services to uninsured, disad-
vantaged residents of New York City. Approximately 20%
(n=17,452) of the population of the NMCSP catchment area is
composed of individuals aged 50–64 years, living at or below 250%
of the federal poverty level, with no medical health insurance.16
Recruitment to the program is accomplished through a vast
outreach network that interfaces with local businesses, churches
and faith-based organizations, schools and health fairs, political
liaisons, social and cultural groups, senior centers, housing projects,
and social clubs using bilingual lay health educators. Residents,
aged Z50 years, who have no medical health insurance coverage,
with family household incomer250% of the federal poverty level,
are at average risk for colorectal cancer, and due for CRC screening
are eligible to receive a fecal-based CRC screening test.
Using a standardized screening intake form, sociodemographic
information was ascertained. All patients were asked a series of
questions to assess CRC screening history (ever screened in the past,
where screened, type of test used, and date of last screening) and risk
for CRC (personal and/or family history of CRC or adenomatous
polyps in one first-degree relative before age 60 years or two first-
degree relatives at any age, family history of hereditary CRCsyndromes, or personal history of inflammatory bowel disease,
chronic ulcerative colitis, or Crohn’s disease). Those who were
current with CRC screening (fecal-based test within the past 12
months, flexible sigmoidoscopy within the past 5 years, or colono-
scopy within the past 10 years) were ineligible to receive CRC
screening services at that time and were recontacted in the future.
As described elsewhere,17 those at average risk for CRC were
offered a fecal-based screening test. Individuals reporting a
personal or family history of colorectal cancer or adenomatous
polyps, inflammatory bowel disease, and hereditary CRC syn-
dromes were referred for a gastroenterology consult, usually
leading to colonoscopy. Those presenting with symptoms, such
as abdominal or rectal mass or prolonged rectal bleeding with
change in bowel habits, were not eligible for fecal-based or
endoscopic screening through this program. Any person diag-
nosed with CRC through the program is eligible to receive case
management services, including treatment and assistance in
obtaining insurance coverage through the New York State
Medicaid Cancer Treatment Program.
Fecal-Based CRC Screening Tests
From January 1, 1998, through December 31, 2006, patients at
average risk for CRC were given a traditional gFOBT kit with three
individual specimen slides (Hemoccults II, Beckman Coulter, Inc.,
Brea CA) that were purchased from and tested by the Columbia
University Medical Center laboratory. In September 2006, fecal
immunochemical testing was introduced and new patients were
provided InSures (Enterix, Inc., Edison NJ), which required two
rather than three sequential specimens and no dietary restrictions.
CRC Education and Kit Distribution
Eligible participants were educated by lay health educators at the time
of enrollment about colorectal cancer, risk factors, and the impor-
tance of early detection. Using the “teach back” method,18 education
was performed in either English or Spanish at the preference of the
patient by bilingual lay health educators. All written program
materials were translated into Spanish and back-translated into
English to ensure accurate communication of the original intent by
native speakers. Materials were prepared at the sixth-grade reading
level determined by the Flesch–Kincaid method.19 Each educational
session was approximately 10–12 minutes in duration.
For traditional gFOBT, patients were asked to collect a portion
of three separate sequential bowel movements and inoculate test
cards. Both written and verbal instructions, in English or Spanish,
regarding dietary restrictions and specific preparation of the toilet
were provided. For FIT, a physical demonstration of the fecal
specimen collection procedure using PlayDohs as simulated feces
was also performed to facilitate self-efficacy in the specimen
collection process.
As approximately 30% of those screened with FIT in the year
this test was introduced had previously screened with gFOBT, this
specimen collection simulation was introduced to demonstrate the
technique and highlight the differences between the two proce-
dures. Participants were provided a fecal test kit and instructed to
complete the test at home and return it within 2 weeks of final
specimen collection (the third for gFOBT and the second for FIT).
All laboratory forms were pre-filled, leaving only the date of
specimen collection to be entered by the patient. Patients werewww.ajpmonline.org
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Partnership or mailing it directly to the laboratory in a provided
self-addressed, stamped envelope. Written and telephone
reminders were deployed after 2 weeks to provide support, answer
questions, and encourage the participant to return the kit.
Replacement kits were provided as needed.Table 1. Demographic characteristics of uninsured,
average-risk individuals aged Z50 years obtaining







Age at first screening (years)
50–54 3,751 (48.6) 2,264 (45.7) 1,487 (53.9)
55–59 2,013 (26.1) 1,310 (26.5) 703 (25.5)
60–64 1,268 (16.4) 890 (18.0) 378 (13.7)
Z65 678 (8.8) 487 (9.8) 191 (6.9)
Gender
Male 1,374 (17.8) 972 (19.6) 402 (14.6)
Female 6,336 (82.2) 3,979 (80.4) 2,357 (85.4)
Race




858 (11.3) 414 (8.4) 444 (16.1)
White 2,139 (27.7) 922 (18.6) 1,217 (44.1)
Other 1739 (22.4) 1,359 (27.4) 380 (13.8)
Ethnicity
Hispanic 3,486 (45.2) 2,065 (41.7) 1,421 (51.5)Data Analysis
De-identified records of all uninsured persons agedZ50 years and
at average risk for CRC who sought colorectal cancer screening
services through the NMCSP were examined. Those who completed
a fecal-based screening test between January 1, 1998 and December
31, 2010 were included in this analysis. To evaluate demographic
characteristics, the first screening record for each patient in the data
set (unduplicated sample, n¼7,710) was examined and, to assess
screening characteristics, all patient encounters over time (dupli-
cated sample, n¼11,489) were included.
Age at first screening; self-reported race (Asian, black/African
American, white, and other) and ethnicity (Hispanic versus
non-Hispanic); and country of origin dichotomized as U.S.-born
versus foreign born was collected at time of program intake.
Any single positive fecal sample was considered a positive screen-
ing test. The mean number of days between kit distribution
and test result was calculated among those who completed
screening. Clinical findings were categorized as colorectal
cancer, adenomatous polyps, or non-neoplastic findings, including
inflammatory bowel disease, hemorrhoids, and diverticular
disease.
The number of colorectal cancers detected per year was also
calculated as well as positive predictive value (number of true
positive FIT/FOBT tests defined as those followed by a colono-
scopy that detected precancerous polyps or CRC divided by the
number of true positive FIT/FOBT tests plus positive FIT/FOBT
tests where the colonoscopy results were negative [false positive
FIT/FOBT], expressed as a percentage) and adenoma detection
rate (number of colonoscopies that detected precancerous
polyps divided by the number of total colonoscopies performed
as a result of a positive FIT/FOBT). Based on the low rescreen-
ing rates and low positive test rates, we estimated that
correlation related to multiple individuals screened multiple
times in the program would be minimal and thus assumed
independence between observations for analysis of the dupli-
cated sample.
Descriptive analyses using chi-square and Student’s t-tests were
performed to assess associations between test methodology and
covariates, respectively. Values of po0.05 were considered statisti-
cally significant. Study procedures were approved by the Columbia
University Medical Center and New York State Department of
Health IRBs, and all analysis was conducted in 2013 using SAS,
version 9.2 (SAS Institute Inc., Cary NC). A waiver of written




6,824 (88.5) 4,449 (89.9) 2,375 (86.1)
Note: Other race includes American Indian, Alaskan Native, Native
Hawaiian, Pacific Islander, more than one race, and others.
CRC, colorectal cancer; FIT, fecal immunochemical testing; gFOBT,
guaiac-based fecal occult blood testingResults
A total of 7,710 patients agedZ50 years completed CRC
screenings (4,951 gFOBT and 2,759 FIT) at the NMCSP
between 1998 and 2010. Patients were young (48.6% aged] ]]]]50–54 years) at first screening through the program,
predominantly female (82.2%); Hispanic (45.2%); and
foreign born (88.5%) (Table 1). Among those using
gFOBT versus FIT, more Asians (45.6% vs 26.0%) and
other races (27.4% vs 13.8%) and fewer whites (18.6% vs
44.1%) and blacks (8.4% vs 16.1%) were screened using
gFOBT than FIT. Those completing FIT were younger
(50–54 years) (po0.001); female (po0.001); white
(po0.001); and Hispanic (po0.001) compared with
those using gFOBT.
Compared with those who screened with gFOBT, FIT
users were more likely to have a positive CRC screening
test (3.2% vs 1.5%, po0.0001) and the adenoma detec-
tion rate of colonoscopies following positive FIT was
greater than those following positive gFOBT (18.2% vs
11.8%, p¼0.002) (Table 2). The positive predictive value
of the screening test, proportion of those who completed
diagnostic colonoscopy, and clinical findings on







Positive 109 (1.5) 139 (3.2)
Negative 7,100 (98.5) 4,141 (96.8)
Positive predictive value (%) 27.5 28.1 0.92
Completed colonoscopy
after positive screen
84 (77.1) 117 (84.2) 0.16
Clinical findings 0.08
Colorectal cancera 6 (7.1) 2 (1.7)
Adenomatous polyps 24 (28.6) 37 (31.1)
Non-neoplastic findingsb 54 (64.3) 80 (67.2)
Adenoma detection rate 24 (11.8) 37 (18.2) 0.002
Note: Boldface indicates statistical significance.
agFOBT: 6 CRC / 9 years ¼ 0.67 CRC per year versus FIT: 2 CRC / 4 years ¼ 0.50 CRC per year
bInflammatory bowel disease, hemorrhoids, other benign findings, and diverticular disease
CRC, colorectal cancer; FIT, fecal immunochemical testing; gFOBT, guaiac-based fecal occult blood testing
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based screening tests (Table 2). Cancers detected per year
(0.67 for gFOBT vs 0.5 for FIT) were comparable for each
test type. The mean turnaround time between kit
distribution and test result for returned tests was shorter
for FIT than for gFOBT (23.3 days vs 26.5 days,
po0.001).
Discussion
The NMCSP, funded by the NYSDOH and the CDC, has
provided free breast, cervical, and colorectal cancer
screening to uninsured adults in Manhattan since 1998.
The current study examined annual CRC screening
compliance with gFOBT and FIT over a 13-year period,
with the aim of evaluating repeat screening adherence
and colonoscopic findings among those testing positive
with these two fecal-based tests.
Compared with those who screened with gFOBT, FIT
users were younger at first CRC screening and more
likely to have a positive CRC screening test. The test
positivity rate with FIT was double that of gFOBT in this
patient population, and although the FIT positivity rate
was relatively low in comparison to rates reported among
European populations,20–22 the finding of a higher
positivity rate for FIT over gFOBT is consistent with
that observed by others.15,23,24 More important, adenoma
detection was significantly greater (p=0.002) using FIT,
indicating a higher likelihood of detecting precancerous
lesions and preventing future cancer.This study presents findings
of a community-based CRC
screening program that pro-
vides fecal-based CRC testing
for average-risk, low-income,
uninsured adults. The patient
population is composed of
predominantly female and
foreign-born persons residing
in northern Manhattan. Many
patients are not fluent in Eng-
lish and have low literacy levels,
even in their native language,25
thus necessitating special meas-
ures to accommodate their par-
ticular language, educational,
and literacy needs. Therefore,
the NMCSP has historically
provided face to face CRC edu-
cation at the time of kit distri-
bution by bilingual health
educators, whose role is com-
parable to that of patient navi-gators in that they keep in contact with the patient until
the screening test is complete, assess barriers, and
provide counseling and education.
Other studies have demonstrated that the high level of
effectiveness of patient navigators is attributed to their
training to identify and address barriers, their cultural
and linguistic concordance with the targeted patient
population, and their ability to provide tailored, relevant
education and assistance, particularly to minority and
disadvantaged populations.26–28
Several RCTs have shown that FIT enhances screening
participation and is superior to gFOBT in detecting
advanced neoplasia.9,12,15,23,29 In Europe, where
population-based CRC screening with fecal occult blood
testing is commonplace, FIT screening completion rates
range between 49.7% and 64.7%.20–22,30 Whereas Euro-
pean programs typically identify eligible individuals
using national databases and invite screening participa-
tion, generally by providing test kits through the mail, the
NMCSP relies predominantly on hospital in-reach and
community outreach with face to face education and
personalized follow-up.
This study provides insight to CRC screening with fecal
tests in a community setting and demonstrates the
recruitment, education, and patient management systems
utilized to effectively reach and screen a vulnerable
population—disadvantaged, minority, low-income resi-
dents of New York City who are medically uninsured.
This program exemplifies many of the key findings
reported regarding the implementation of the CDCwww.ajpmonline.org
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specifically the importance of tailored outreach and
education that defers to the local culture and wisdom.31,32
After introduction of FIT, the mean number of days
between kit distribution and test result decreased by 3
days. These findings can be partially explained by the fact
that FIT requires less fecal manipulation, fewer test
samples, no dietary restrictions, is generally more pref-
erable to patients,7,33,34 and is promoted by one-on-one
education and patient navigation. It is also possible that
the implementation of FIT specimen collection demon-
stration may have contributed to patient self-efficacy in
performing the specimen collection and thus, the higher
rates of compliance with FIT over gFOBT.
As with all studies, there were several limitations to
this study. Two different sets of patients over two
different time periods were compared to make general-
izations about the relative differences in the two types of
fecal-based CRC screening tests. Although there were
statistically significant differences in demographic char-
acteristics in those who screened with FIT versus gFOBT,
these differences more likely reflect the environmental
changes, program policy modifications, and fluctuations
in the composition of the study population rather than
true differences related to the test alone. It is also possible
that the assumption of independence among multiple
observations over time may have biased the findings.
During the study period, public service campaigns,
such as Katie Couric’s televised colonoscopy and a
citywide program to increase colonoscopy screening
launched by the New York City Department of Health
and Mental Hygiene,35 heightened public awareness of
CRC and may have increased the demand for CRC
screening during the study period. In addition, in 2008,
the U.S. Preventive Services Task Force issued a recom-
mendation endorsing the use of high-sensitivity tests
such as FIT to screen for CRC.5 Although these historic
events contributed to overall CRC screening in New York
City over the study period, many of these efforts were
primarily aimed at insured populations, guiding those
with medical coverage to seek out colonoscopy at
hospitals through referrals made by their primary care
providers.
The population served by NMCSP is primarily a
disadvantaged, Hispanic, and Asian population, which
may limit the generalizability of these findings to other
settings and persons of other cultural backgrounds. Some
patients had previously screened for CRC using gFOBT
and may have been more amenable to adopting FIT;
however, this is unlikely to impact the findings of higher
test positivity and greater adenoma detection with FIT.
This study is also limited in that data were collected by
the NYSDOH for administrative reasons, not research.] ]]]]For example, although the system allowed and the
program encouraged documentation of all distributed
kits, this was not performed consistently by all sites.
Thus, it was not possible to determine rates of screening
by test type because it was not possible to identify all
persons who were educated and given test kits but who
refused to complete CRC screening.
Reasons for the shift in age at first screening with FIT
over gFOBT is likely reflective of improved staffing levels
after 2008 and more intense recruitment from the breast
cancer screening arm of the program, where women are
eligible for services at age 40 years and are captured for
CRC screening as soon as they become age-eligible.
Racial differences observed between the use of the two
tests may be indicative of changes in program outreach
efforts and availability of resources during the respective
time frames. Because the studied patient population is
highly transient and often lost to follow-up, examining
adherence to fecal-based CRC screening over time was
not possible.Conclusions
In population-based screening settings, fecal-based CRC
screening is an effective method for early CRC detection
and prevention among uninsured individuals who lack a
usual source of care and have limited healthcare system
access. The improved adenoma detection rate and greater
number of screening tests over time favor the use of FIT
over gFOBT for CRC screening among uninsured
populations in northern Manhattan. Building upon these
findings, future studies adjusting for different screening
tests, multiple tests per person, and patient demographics
would further increase the understanding of population-
based CRC screening using fecal tests.This study was supported in part by a grant from the New York
State Department of Health, Bureau of Chronic Disease
Control, by NIH grant no. 1U24 CA171524 to Grace Clarke
Hillyer, and by NIH grant no. T32 DK083256-04 to Daniel
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